Oral propranolol for infantile hemangiomas beyond the proliferative phase

Infantile hemangiomas grow rapidly during infancy followed by gradual involution. After involution, residual lesions sometimes remain. Despite the prognosis for eventual involution, infantile hemangiomas often cause great psychosocial morbidity that affects patients and their parents. Oral propranol...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2018-10, Vol.45 (10), p.1199-1202
Main Authors: Kagami, Shinji, Katori, Tatsuo
Format: Article
Language:English
Subjects:
Administration, Oral
Asthma
Asthma - chemically induced
Exanthema
Exanthema Subitum - chemically induced
Female
Hemangioma
Hemangioma - diagnostic imaging
Hemangioma - drug therapy
Humans
Infant
infantile hemangioma
Japanese
Male
Morbidity
Patients
Photography
post‐proliferative phase
proliferation
Propranolol
Propranolol - therapeutic use
Skin Neoplasms - diagnostic imaging
Skin Neoplasms - drug therapy
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infantile hemangiomas grow rapidly during infancy followed by gradual involution. After involution, residual lesions sometimes remain. Despite the prognosis for eventual involution, infantile hemangiomas often cause great psychosocial morbidity that affects patients and their parents. Oral propranolol usually induces earlier involution and redness reduction in infantile hemangiomas in the proliferative phase. However, to evaluate the effectiveness of oral propranolol for infantile hemangiomas beyond the proliferative phase is difficult because of spontaneous regression. We report five Japanese patients treated with 2 mg/kg per day of oral propranolol for infantile hemangiomas beyond the proliferative phase and compared with three untreated patients. After the oral propranolol treatment for 25 weeks, all the treated patients exhibited earlier color fading than untreated patients. Four patients reached nearly complete resolution. Adverse events occurred in three patients: cold, exanthema subitum and suspected of bronchial asthma, respectively. The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months. Recurrence after termination of treatment was not seen. Oral propranolol (2 mg/kg per day) is a safe and effective treatment for Japanese patients with infantile hemangiomas beyond the proliferative phase.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.14581